Clinical Trials Update: Aug. 8, 2005
Cervical Dysplasia Strokes Renal Cell Carcinoma
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
This study seeks women between the ages of 13 to 25 with an abnormal Pap smear to evaluate an investigational therapy for moderate-to-severe cervical dysplasia. Clinical testing will determine if you qualify. Clinical tests are free of charge and you will receive results even if you do not qualify for the study. Reimbursement for time and travel is available. Research site located in Albuquerque, NM.
Research will evaluate whether study medication will affect breathing, relax tightness in the muscles, and allow the wrist, fingers, and elbow to be straightened. Study will last for about 32 weeks; if you participate you will be asked to make nine visits to the study center, where you will have injections into your arm and hand. Research site located in Pittsburgh, Penn.
Renal Cell Carcinoma
This is a phase 2 study of two dose levels of IMOxine (HYB2055 for injection) in patients with metastatic or locally recurrent clear cell renal carcinoma. This is not chemotherapy but rather a weekly injection that may stimulate your own immune system to challenge tumor growth. It is expected to last 24 weeks or longer with weekly examination visits. Participants must be 18 or older, must have histologically confirmed, stage IV clear cell renal carcinoma, have a measurable lesion using RECIST criteria and a history of no more than one previous therapeutic treatment that failed or was not tolerable. Research sites located throughout the United States.
Copyright 2005 CenterWatch. All rights reserved.